The Digest’s 2026 Multi-Slide Guide to DSM-Firmenich

dsm-firmenich is advancing its strategic portfolio transformation by separating its Animal Nutrition & Health business, with an exit expected in 2025. The company is focusing on high-growth segments in Nutrition, Health, and Beauty, showcasing innovations like plant-based tuna alternatives and microbiome-targeted gut health solutions. Financial highlights include a planned €1 billion share buyback, the completion of a vitamin transformation program delivering €200 million in savings, and a 2025 outlook projecting adjusted EBITDA of at least €2.4 billion.